Effectiveness of remdesivir-based therapy for moderate COVID-19 : comparison of Omicron and other variant phases
Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been reported. In this single-center retrospective study, we first compared the clinical effectiveness of remdesivir-based therapy between Omicron and other variant phases of moderate COVID-19 in a real-world setting. Between Dec 2020 and July 2022, a total of 406 patients with COVID-19 pneumonia were treated with remdesivir-based therapy on admission. The oxygen deterioration rate after initiation of treatment significantly decreased in the Omicron variant phase compared to the alpha and delta variant phases. In an adjusted multivariate Cox proportional hazards model, Omicron variant phase was significantly associated with delayed oxygen deterioration and early recovery from hypoxia. These favorable outcomes during the Omicron variant phase, compared to previous variant phases, might be due to the attenuation and the popularization of vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of chemotherapy (Florence, Italy) - 36(2024), 2 vom: 15. März, Seite 127-132 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suzuki, Atsushi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3QKI37EEHE |
|---|
| Anmerkungen: |
Date Completed 15.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/1120009X.2023.2289268 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365355461 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365355461 | ||
| 003 | DE-627 | ||
| 005 | 20240315232924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/1120009X.2023.2289268 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM365355461 | ||
| 035 | |a (NLM)38044564 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suzuki, Atsushi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of remdesivir-based therapy for moderate COVID-19 |b comparison of Omicron and other variant phases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Remdesivir is an antiviral drug for the treatment of coronavirus disease 2019 (COVID-19), and the sustained antiviral activity against Omicron variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been reported. In this single-center retrospective study, we first compared the clinical effectiveness of remdesivir-based therapy between Omicron and other variant phases of moderate COVID-19 in a real-world setting. Between Dec 2020 and July 2022, a total of 406 patients with COVID-19 pneumonia were treated with remdesivir-based therapy on admission. The oxygen deterioration rate after initiation of treatment significantly decreased in the Omicron variant phase compared to the alpha and delta variant phases. In an adjusted multivariate Cox proportional hazards model, Omicron variant phase was significantly associated with delayed oxygen deterioration and early recovery from hypoxia. These favorable outcomes during the Omicron variant phase, compared to previous variant phases, might be due to the attenuation and the popularization of vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Delta | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a alpha | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a remdesivir | |
| 650 | 7 | |a remdesivir |2 NLM | |
| 650 | 7 | |a 3QKI37EEHE |2 NLM | |
| 650 | 7 | |a Oxygen |2 NLM | |
| 650 | 7 | |a S88TT14065 |2 NLM | |
| 650 | 7 | |a Adenosine Monophosphate |2 NLM | |
| 650 | 7 | |a 415SHH325A |2 NLM | |
| 650 | 7 | |a Alanine |2 NLM | |
| 650 | 7 | |a OF5P57N2ZX |2 NLM | |
| 700 | 1 | |a Fukumitsu, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Fukihara, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Katano, Takuma |e verfasserin |4 aut | |
| 700 | 1 | |a Kako, Hisashi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Yuri |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Niimi, Akio |e verfasserin |4 aut | |
| 700 | 1 | |a Imaizumi, Kazuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yamaguchi, Etsuro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of chemotherapy (Florence, Italy) |d 1989 |g 36(2024), 2 vom: 15. März, Seite 127-132 |w (DE-627)NLM012678473 |x 1973-9478 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2024 |g number:2 |g day:15 |g month:03 |g pages:127-132 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/1120009X.2023.2289268 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2024 |e 2 |b 15 |c 03 |h 127-132 | ||